» Articles » PMID: 38716641

Effectiveness of Calcipotriol/betamethasone Dipropionate Aerosol Foam in Patients with Small Versus Large Plaque Psoriasis in Routine Practice in South Korea

Overview
Journal J Dermatol
Specialty Dermatology
Date 2024 May 8
PMID 38716641
Authors
Affiliations
Soon will be listed here.
Abstract

Small plaque psoriasis is the typical form of chronic plaque psoriasis affecting adults in South Korea. The effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) aerosol foam for large and small psoriasis plaques has not previously been examined. We performed a post hoc analysis of a recent, 4-week observational study of Cal/BD aerosol foam use in routine clinical practice in South Korea. Investigator Global Assessment response ([IGA] 0/1 at week 4), Patient Global Assessment response ([PaGA] 0/1 at week 4), change in Psoriasis Area and Severity Index (PASI), changes in psoriasis symptom scores, change in the Dermatology Life Quality Index (DLQI), and the proportion of patients achieving DLQI ≤5 were analyzed for patients with small (≤5 cm; n = 131) or large (>5 cm; n = 35) baseline plaque size. IGA response rates were similar for patients with small and large plaques (59.5% and 51.4% respectively). Similarly, there was no significant difference between the small and large groups in mean change in PASI (-2.20 vs -3.34), the proportions of patients with DLQI ≤5 (62.3% vs 54.3%) or PaGA 0/1 (29.2% vs 40.0%). Mean improvements in DLQI (-4.04 vs -6.20) and in psoriasis symptoms including itching (-1.50 vs -2.83), sleep loss (-0.67 vs -1.89), dryness (-1.57 vs -2.97), scaling (-1.21 vs -3.57), and redness (-1.17 vs -3.11) were greater in patients with large plaques than those with small plaques. Itching and DLQI differences were not statistically significant after adjustment for baseline characteristics. Stratification by body surface area affected eliminated statistically significant differences between the groups for most outcomes. In conclusion, this analysis suggests that Cal/BD aerosol foam is an effective, well-accepted treatment for adult patients with the small plaques typical of chronic plaque psoriasis in South Korea, as well as for those with large plaques.

Citing Articles

Effectiveness of calcipotriol/betamethasone dipropionate aerosol foam in patients with small versus large plaque psoriasis in routine practice in South Korea.

Jo S, Park C, Bang C, Jeong K, Shin B, Kim D J Dermatol. 2024; 51(7):1010-1016.

PMID: 38716641 PMC: 11483922. DOI: 10.1111/1346-8138.17253.

References
1.
Campanati A, Atzori L, Potenza C, Damiani G, Bianchi L, Corazza M . Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study. Dermatol Ther. 2021; 34(5):e15077. PMC: 9285427. DOI: 10.1111/dth.15077. View

2.
Jo S, Park C, Bang C, Jeong K, Shin B, Kim D . Effectiveness of calcipotriol/betamethasone dipropionate aerosol foam in patients with small versus large plaque psoriasis in routine practice in South Korea. J Dermatol. 2024; 51(7):1010-1016. PMC: 11483922. DOI: 10.1111/1346-8138.17253. View

3.
Kim J, Oh C, Jeon J, Baek Y, Ahn J, Kim D . Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol. 2016; 136(1):161-172. PMC: 4731034. DOI: 10.1038/JID.2015.378. View

4.
Khosravi-Hafshejani T, Ghoreishi M, Vera Kellet C, Crawford R, Martinka M, Dutz J . Small plaque psoriasis re-visited: A type of psoriasis mediated by a type-I interferon pathway. Exp Dermatol. 2021; 31(5):753-763. DOI: 10.1111/exd.14513. View

5.
Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M . Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018; 45(11):1345-1348. DOI: 10.1111/1346-8138.14617. View